Global and United States Drugs for Vulvovaginal Candidiasis Market Insights, Forecast to 2027

Global and United States Drugs for Vulvovaginal Candidiasis Market Insights, Forecast to 2027

Table of Contents
1 Study Coverage
1.1 Drugs for Vulvovaginal Candidiasis Product Introduction
1.2 Market by Type
1.2.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type
1.2.2 Cream
1.2.3 Pessary
1.2.4 Other
1.3 Market by Application
1.3.1 Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application
1.3.2 Hospital & Clinic
1.3.3 Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Drugs for Vulvovaginal Candidiasis Market Size, Estimates and Forecasts
2.1.1 Global Drugs for Vulvovaginal Candidiasis Revenue 2016-2027
2.1.2 Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027
2.2 Global Drugs for Vulvovaginal Candidiasis, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Drugs for Vulvovaginal Candidiasis Historical Market Size by Region (2016-2021)
2.3.1 Global Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Drugs for Vulvovaginal Candidiasis Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Drugs for Vulvovaginal Candidiasis Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027)
2.4.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027)
3 Global Drugs for Vulvovaginal Candidiasis Competitor Landscape by Players
3.1 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Sales
3.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturer (2016-2021)
3.1.2 Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue
3.2.1 Key Drugs for Vulvovaginal Candidiasis Manufacturers Covered: Ranking by Revenue
3.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2021)
3.2.3 Global Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Drugs for Vulvovaginal Candidiasis Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Drugs for Vulvovaginal Candidiasis Revenue in 2020
3.2.6 Global Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Drugs for Vulvovaginal Candidiasis Price by Manufacturers
3.4 Global Drugs for Vulvovaginal Candidiasis Manufacturing Base Distribution, Product Types
3.4.1 Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
3.4.3 Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Type (2016-2021)
4.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021)
4.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021)
4.1.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Drugs for Vulvovaginal Candidiasis Market Size Forecast by Type (2022-2027)
4.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027)
4.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027)
4.2.3 Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Drugs for Vulvovaginal Candidiasis Market Size by Application (2016-2021)
5.1.1 Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021)
5.1.2 Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021)
5.1.3 Drugs for Vulvovaginal Candidiasis Price by Application (2016-2021)
5.2 Drugs for Vulvovaginal Candidiasis Market Size Forecast by Application (2022-2027)
5.2.1 Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027)
5.2.2 Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027)
5.2.3 Global Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2022-2027)
6 United States by Players, Type and Application
6.1 United States Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
6.1.1 United States Drugs for Vulvovaginal Candidiasis Sales YoY Growth 2016-2027
6.1.2 United States Drugs for Vulvovaginal Candidiasis Revenue YoY Growth 2016-2027
6.1.3 United States Drugs for Vulvovaginal Candidiasis Market Share in Global Market 2016-2027
6.2 United States Drugs for Vulvovaginal Candidiasis Market Size by Players (International and Local Players)
6.2.1 United States Top Drugs for Vulvovaginal Candidiasis Players by Sales (2016-2021)
6.2.2 United States Top Drugs for Vulvovaginal Candidiasis Players by Revenue (2016-2021)
6.3 United States Drugs for Vulvovaginal Candidiasis Historic Market Review by Type (2016-2021)
6.3.1 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
6.3.2 United States Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2016-2021)
6.3.3 United States Drugs for Vulvovaginal Candidiasis Price by Type (2016-2021)
6.4 United States Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Type (2022-2027)
6.4.1 United States Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027)
6.4.2 United States Drugs for Vulvovaginal Candidiasis Revenue Forecast by Type (2022-2027)
6.4.3 United States Drugs for Vulvovaginal Candidiasis Price Forecast by Type (2022-2027)
6.5 United States Drugs for Vulvovaginal Candidiasis Historic Market Review by Application (2016-2021)
6.5.1 United States Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
6.5.2 United States Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2016-2021)
6.5.3 United States Drugs for Vulvovaginal Candidiasis Price by Application (2016-2021)
6.6 United States Drugs for Vulvovaginal Candidiasis Market Estimates and Forecasts by Application (2022-2027)
6.6.1 United States Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027)
6.6.2 United States Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027)
6.6.3 United States Drugs for Vulvovaginal Candidiasis Price Forecast by Application (2022-2027)
7 North America
7.1 North America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
7.2 North America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
7.2.1 North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021)
7.2.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
8.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Region
8.2.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021)
8.2.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam
9 Europe
9.1 Europe Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
9.2 Europe Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
9.2.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021)
9.2.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
10.2 Latin America Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
10.2.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021)
10.2.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Facts & Figures by Country
11.2.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021)
11.2.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 U.A.E
12 Company Profiles
12.1 Bayer
12.1.1 Bayer Corporation Information
12.1.2 Bayer Description and Business Overview
12.1.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
12.1.5 Bayer Recent Development
12.2 Perrigo
12.2.1 Perrigo Corporation Information
12.2.2 Perrigo Description and Business Overview
12.2.3 Perrigo Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Perrigo Drugs for Vulvovaginal Candidiasis Products Offered
12.2.5 Perrigo Recent Development
12.3 J & J
12.3.1 J & J Corporation Information
12.3.2 J & J Description and Business Overview
12.3.3 J & J Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.3.4 J & J Drugs for Vulvovaginal Candidiasis Products Offered
12.3.5 J & J Recent Development
12.4 Pfizer
12.4.1 Pfizer Corporation Information
12.4.2 Pfizer Description and Business Overview
12.4.3 Pfizer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Pfizer Drugs for Vulvovaginal Candidiasis Products Offered
12.4.5 Pfizer Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Corporation Information
12.5.2 Bristol-Myers Squibb Description and Business Overview
12.5.3 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Products Offered
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Effik
12.6.1 Effik Corporation Information
12.6.2 Effik Description and Business Overview
12.6.3 Effik Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Effik Drugs for Vulvovaginal Candidiasis Products Offered
12.6.5 Effik Recent Development
12.7 Teva
12.7.1 Teva Corporation Information
12.7.2 Teva Description and Business Overview
12.7.3 Teva Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Teva Drugs for Vulvovaginal Candidiasis Products Offered
12.7.5 Teva Recent Development
12.8 Sanofi
12.8.1 Sanofi Corporation Information
12.8.2 Sanofi Description and Business Overview
12.8.3 Sanofi Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Sanofi Drugs for Vulvovaginal Candidiasis Products Offered
12.8.5 Sanofi Recent Development
12.9 Cisen Pharmaceutical
12.9.1 Cisen Pharmaceutical Corporation Information
12.9.2 Cisen Pharmaceutical Description and Business Overview
12.9.3 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Products Offered
12.9.5 Cisen Pharmaceutical Recent Development
12.10 Kingyork Group
12.10.1 Kingyork Group Corporation Information
12.10.2 Kingyork Group Description and Business Overview
12.10.3 Kingyork Group Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Kingyork Group Drugs for Vulvovaginal Candidiasis Products Offered
12.10.5 Kingyork Group Recent Development
12.11 Bayer
12.11.1 Bayer Corporation Information
12.11.2 Bayer Description and Business Overview
12.11.3 Bayer Drugs for Vulvovaginal Candidiasis Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Bayer Drugs for Vulvovaginal Candidiasis Products Offered
12.11.5 Bayer Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Drugs for Vulvovaginal Candidiasis Industry Trends
13.2 Drugs for Vulvovaginal Candidiasis Market Drivers
13.3 Drugs for Vulvovaginal Candidiasis Market Challenges
13.4 Drugs for Vulvovaginal Candidiasis Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Drugs for Vulvovaginal Candidiasis Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Cream
Table 3. Major Manufacturers of Pessary
Table 4. Major Manufacturers of Other
Table 5. Global Drugs for Vulvovaginal Candidiasis Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 6. Global Drugs for Vulvovaginal Candidiasis Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Drugs for Vulvovaginal Candidiasis Sales by Regions (2016-2021) & (K Units)
Table 8. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Regions (2016-2021)
Table 9. Global Drugs for Vulvovaginal Candidiasis Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Region (2022-2027) & (K Units)
Table 11. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Drugs for Vulvovaginal Candidiasis Sales by Manufacturers (2016-2021) (K Units)
Table 15. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Drugs for Vulvovaginal Candidiasis Manufacturers by Revenue (US$ Million) in 2020
Table 17. Drugs for Vulvovaginal Candidiasis Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Drugs for Vulvovaginal Candidiasis Revenue Share by Manufacturers (2016-2021)
Table 19. Global Drugs for Vulvovaginal Candidiasis Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Drugs for Vulvovaginal Candidiasis by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Vulvovaginal Candidiasis as of 2020)
Table 21. Key Manufacturers Drugs for Vulvovaginal Candidiasis Price (2016-2021) (USD/Unit)
Table 22. Drugs for Vulvovaginal Candidiasis Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Drugs for Vulvovaginal Candidiasis Product Type
Table 24. Date of International Manufacturers Enter into Drugs for Vulvovaginal Candidiasis Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Vulvovaginal Candidiasis Sales by Type (2016-2021) (K Units)
Table 27. Global Drugs for Vulvovaginal Candidiasis Sales Share by Type (2016-2021)
Table 28. Global Drugs for Vulvovaginal Candidiasis Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2016-2021)
Table 30. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Table 31. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Type (2022-2027) & (K Units)
Table 32. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) Forecast by Type (2022-2027) & (USD/Unit)
Table 36. Global Drugs for Vulvovaginal Candidiasis Sales by Application (2016-2021) (K Units)
Table 37. Global Drugs for Vulvovaginal Candidiasis Sales Share by Application (2016-2021)
Table 38. Global Drugs for Vulvovaginal Candidiasis Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2016-2021)
Table 40. Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Table 41. Global Drugs for Vulvovaginal Candidiasis Sales Forecast by Application (2022-2027) & (K Units)
Table 42. Global Drugs for Vulvovaginal Candidiasis Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Drugs for Vulvovaginal Candidiasis Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Drugs for Vulvovaginal Candidiasis Average Selling Price (ASP) Forecast by Application (2022-2027) & (USD/Unit)
Table 46. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) of Key Companies (2016-2021)
Table 47. United States Drugs for Vulvovaginal Candidiasis Sales Share by Company (2016-2021)
Table 48. United States Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) by Company (2016-2021)
Table 49. United States Drugs for Vulvovaginal Candidiasis Revenue Share by Company (2016-2021)
Table 50. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2016-2021)
Table 51. United States Drugs for Vulvovaginal Candidiasis Sales Share by Type (2016-2021)
Table 52. United States Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. United States Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2016-2021)
Table 54. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Type (2022-2027)
Table 55. United States Drugs for Vulvovaginal Candidiasis Sales Share by Type (2022-2027)
Table 56. United States Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. United States Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2022-2027)
Table 58. United States Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Type (2022-2027)
Table 59. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2016-2021)
Table 60. United States Drugs for Vulvovaginal Candidiasis Sales Share by Application (2016-2021)
Table 61. United States Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. United States Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2016-2021)
Table 63. United States Drugs for Vulvovaginal Candidiasis Sales (K Units) by Application (2022-2027)
Table 64. United States Drugs for Vulvovaginal Candidiasis Sales Share by Application (2022-2027)
Table 65. United States Drugs for Vulvovaginal Candidiasis Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. United States Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2022-2027)
Table 67. United States Drugs for Vulvovaginal Candidiasis Price (USD/Unit) by Application (2022-2027)
Table 68. North America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 69. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2021)
Table 70. North America Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Region (2016-2021) & (K Units)
Table 73. Asia Pacific Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2021)
Table 76. Europe Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 77. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2021)
Table 78. Europe Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2021)
Table 80. Latin America Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 81. Latin America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Country (2016-2021) & (K Units)
Table 85. Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country (2016-2021)
Table 88. Bayer Corporation Information
Table 89. Bayer Description and Business Overview
Table 90. Bayer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Bayer Drugs for Vulvovaginal Candidiasis Product
Table 92. Bayer Recent Development
Table 93. Perrigo Corporation Information
Table 94. Perrigo Description and Business Overview
Table 95. Perrigo Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Perrigo Product
Table 97. Perrigo Recent Development
Table 98. J & J Corporation Information
Table 99. J & J Description and Business Overview
Table 100. J & J Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. J & J Product
Table 102. J & J Recent Development
Table 103. Pfizer Corporation Information
Table 104. Pfizer Description and Business Overview
Table 105. Pfizer Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. Pfizer Product
Table 107. Pfizer Recent Development
Table 108. Bristol-Myers Squibb Corporation Information
Table 109. Bristol-Myers Squibb Description and Business Overview
Table 110. Bristol-Myers Squibb Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Bristol-Myers Squibb Product
Table 112. Bristol-Myers Squibb Recent Development
Table 113. Effik Corporation Information
Table 114. Effik Description and Business Overview
Table 115. Effik Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Effik Product
Table 117. Effik Recent Development
Table 118. Teva Corporation Information
Table 119. Teva Description and Business Overview
Table 120. Teva Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. Teva Product
Table 122. Teva Recent Development
Table 123. Sanofi Corporation Information
Table 124. Sanofi Description and Business Overview
Table 125. Sanofi Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Sanofi Product
Table 127. Sanofi Recent Development
Table 128. Cisen Pharmaceutical Corporation Information
Table 129. Cisen Pharmaceutical Description and Business Overview
Table 130. Cisen Pharmaceutical Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 131. Cisen Pharmaceutical Product
Table 132. Cisen Pharmaceutical Recent Development
Table 133. Kingyork Group Corporation Information
Table 134. Kingyork Group Description and Business Overview
Table 135. Kingyork Group Drugs for Vulvovaginal Candidiasis Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
Table 136. Kingyork Group Product
Table 137. Kingyork Group Recent Development
Table 138. Drugs for Vulvovaginal Candidiasis Market Trends
Table 139. Drugs for Vulvovaginal Candidiasis Market Drivers
Table 140. Drugs for Vulvovaginal Candidiasis Market Challenges
Table 141. Drugs for Vulvovaginal Candidiasis Market Restraints
Table 142. Drugs for Vulvovaginal Candidiasis Customers List
Table 143. Drugs for Vulvovaginal Candidiasis Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Drugs for Vulvovaginal Candidiasis Product Picture
Figure 2. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020 & 2027
Figure 3. Cream Product Picture
Figure 4. Pessary Product Picture
Figure 5. Other Product Picture
Figure 6. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020 & 2027
Figure 7. Hospital & Clinic
Figure 8. Pharmacy
Figure 9. Drugs for Vulvovaginal Candidiasis Report Years Considered
Figure 10. Global Drugs for Vulvovaginal Candidiasis Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Drugs for Vulvovaginal Candidiasis Market Size 2016-2027 (US$ Million)
Figure 12. Global Drugs for Vulvovaginal Candidiasis Sales 2016-2027 (K Units)
Figure 13. Global Drugs for Vulvovaginal Candidiasis Market Size Market Share by Region: 2021 Versus 2027
Figure 14. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region (2016-2021)
Figure 15. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Region in 2020
Figure 16. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region (2016-2021)
Figure 17. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Region in 2020
Figure 18. Global Drugs for Vulvovaginal Candidiasis Sales Share by Manufacturer in 2020
Figure 19. The Top 10 and 5 Players Market Share by Drugs for Vulvovaginal Candidiasis Revenue in 2020
Figure 20. Drugs for Vulvovaginal Candidiasis Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 21. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type (2016-2021)
Figure 22. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Type in 2020
Figure 23. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type (2016-2021)
Figure 24. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Type in 2020
Figure 25. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application (2016-2021)
Figure 26. Global Drugs for Vulvovaginal Candidiasis Sales Market Share by Application in 2020
Figure 27. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application (2016-2021)
Figure 28. Global Drugs for Vulvovaginal Candidiasis Revenue Market Share by Application in 2020
Figure 29. United States Drugs for Vulvovaginal Candidiasis Sales Growth Rate 2016-2027 (K Units)
Figure 30. United States Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2027 (US$ Million)
Figure 31. United States Drugs for Vulvovaginal Candidiasis Market Share in Global Market 2016-2027
Figure 32. United States 5 and 10 Largest Drugs for Vulvovaginal Candidiasis Players Market Share by Revenue in Drugs for Vulvovaginal Candidiasis in 2020
Figure 33. United States Drugs for Vulvovaginal Candidiasis Revenue Share by Type (2016-2021)
Figure 34. United States Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Type in 2016 & 2020
Figure 35. United States Drugs for Vulvovaginal Candidiasis Revenue Share by Application (2016-2021)
Figure 36. United States Drugs for Vulvovaginal Candidiasis Revenue Growth Rate by Application in 2016 & 2020
Figure 37. North America Drugs for Vulvovaginal Candidiasis Sales Growth Rate 2016-2021 (K Units)
Figure 38. North America Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2021 (US$ Million)
Figure 39. North America Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2020
Figure 40. North America Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country in 2020
Figure 41. U.S. Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 42. U.S. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Canada Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 44. Canada Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Europe Drugs for Vulvovaginal Candidiasis Sales Growth Rate 2016-2021 (K Units)
Figure 46. Europe Drugs for Vulvovaginal Candidiasis Revenue Growth Rate 2016-2021 (US$ Million)
Figure 47. Europe Drugs for Vulvovaginal Candidiasis Sales Market Share by Country in 2020
Figure 48. Europe Drugs for Vulvovaginal Candidiasis Revenue Market Share by Country in 2020
Figure 49. Germany Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 50. Germany Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 51. France Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 52. France Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 53. U.K. Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 54. U.K. Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 55. Italy Drugs for Vulvovaginal Candidiasis Sales Growth Rate (2016-2021) (K Units)
Figure 56. Italy Drugs for Vulvovaginal Candidiasis Revenue Growth Rate (2016-2021) (US$ Million)
Figure 57. Russia Drug

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global Drugs for Vulvovaginal Candidiasis Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119

According to our LPI (LP Information) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at US$ 798.8 million in 2023. With growing demand in downstream market, the Drugs for Vulvovaginal Candidiasis is forecast to a readjusted size of US$ 890 million by 2030 with a CAGR of 1.6% during review period. The research report highlights the growth potential of the global Drugs for Vulvovaginal Candidiasis market. Drugs for Vulvovaginal Candidiasis are expected t......

Global Bacterial Vaginosis Drug Market Growth (Status and Outlook) 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 132

According to our LPI (LP Information) latest study, the global Bacterial Vaginosis Drug market size was valued at US$ 896.6 million in 2023. With growing demand in downstream market, the Bacterial Vaginosis Drug is forecast to a readjusted size of US$ 1111.1 million by 2030 with a CAGR of 3.1% during review period. The research report highlights the growth potential of the global Bacterial Vaginosis Drug market. Bacterial Vaginosis Drug are expected to show stable growth in the future ma......

Global Contraceptives Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 141

According to our LPI (LP Information) latest study, the global Contraceptives market size was valued at US$ 1870.3 million in 2023. With growing demand in downstream market, the Contraceptives is forecast to a readjusted size of US$ 2237.4 million by 2030 with a CAGR of 2.6% during review period. The research report highlights the growth potential of the global Contraceptives market. Contraceptives are expected to show stable growth in the future market. However, product differentiation,......

Global Drugs for Vulvovaginal Candidiasis Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 108

According to our (Global Info Research) latest study, the global Drugs for Vulvovaginal Candidiasis market size was valued at USD 840.2 million in 2023 and is forecast to a readjusted size of USD 928.4 million by 2030 with a CAGR of 1.4% during review period. The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cu......

Global Menopausal Hot Flashes Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 99

Market Overview of Global Menopausal Hot Flashes market: According to our latest research, the global Menopausal Hot Flashes market looks promising in the next 5 years. As of 2022, the global Menopausal Hot Flashes market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Hot flashes during menopause are symptoms of menopause. They refer to the warmth that occurs during the transition period of ......

Global Bacterial Vaginosis Drug Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 139

Report Overview: This report studies the Bacterial Vaginosis Drug market, Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria. This report includes metronidazole, clindamycin drug and other drugs. The Global Bacterial Vaginosis Drug Market Size was estimated at USD 916.50 million in 2022 and is projected to reach USD 1127.18 million by 202......

Global Drugs for Vulvovaginal Candidiasis Market Research Report 2024 (Status and Outlook)

Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 122

Report Overview: The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for a......

Global Bacterial Vaginosis Drug Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 05-Dec-2023        Price: US 3380 Onwards        Pages: 108

Market Overview of Global Bacterial Vaginosis Drug market: According to our latest research, the global Bacterial Vaginosis Drug market looks promising in the next 5 years. As of 2022, the global Bacterial Vaginosis Drug market was estimated at USD 972.77 million, and it's anticipated to reach USD 1215.68 million in 2028, with a CAGR of 3.79% during the forecast years. Bacterial vaginosis (BV), also known as bacterial vaginosis, non-specific vaginitis is a disease that occurs......

Global Tocolysis Drugs Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 30-Nov-2023        Price: US 3380 Onwards        Pages: 123

Market Overview of Global Tocolysis Drugs market: According to our latest research, the global Tocolysis Drugs market looks promising in the next 5 years. As of 2022, the global Tocolysis Drugs market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Tocolytics are medications used to suppress premature labor. Tocolytic therapy is provided when delivery would result in premature birth, postponi......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs